Medline.ru - | Кровезаменители с газотранпортной функцией на основе гемоглобина

Список литературы

1. Воробьев С.И. Перфторуглеродные эмульсии I и II поколения // Хим.-фарм. журн. – 2009. – Т. 43. – № 4. С. 30-40.

2. Голубев А.М., Белоярцев Ф.Ф., Васильев А.Э., Покровский Ю.Э. Реакции биологических систем при замещении крови эмульсиями фторуглеродов. М.: ТЕИС, 1993.

3. Дьяконов А.Н., Бурданов А.П., Корик В.Е., Коновалов С.В. Применение геленпола при операциях на толстой кишке // Применение инфузионных антигипоксантов и искусственных переносчиков кислорода в хирургии: Сб. науч. тр. / СПб. 1999. С. 16-18.

4. Иваницкий Г.Р. Биофизика на пороге нового тысячелетия: перфторуглеродные среды и газотранспортные кровезаменители // Биофизика – 2001. – Т.46. – № 1. – С. 5-33.

5. Корик В.Е. Применение кровезаменителя-переносчика кислорода на основе модифицированного гемоглобина при лечении больных с тяжелой кровопотерей // Автореф. дисс… канд. мед. наук. – СПб., 2000.

6. Кузнецова Н.П., Гудкин Л.Р., Мишаева Р.Н. Способ получения полигемоглобина с повышенной кислородтранспортной эффективностью / Патент RU 2132687, 1999.

7. Кузнецова Н.П., Гудкин Л.Р., Селиванов Е.А. и др. Кровезаменитель- переносчик кислорода, состав для его получения и способ получения полимерного модифицированного гемоглобина / Патент RU2162707, 2001.

8. Самсонов Г.В. и др. Солевой раствор полимерного гемоглобина / Патент SU183354А3, 1992.

9. Селиванов Е.А., Быстрова И.М., Ханевич М.Д., Парашин М.Е. Экспериментальное и клиническое изучение кровезаменителя-переносчика кислорода на основе модифицированного гемоглобина // Физиологически активные вещества на основе перфторуглеродов в военной медицине: Сб. матер. науч. конф. / СПб. 1997. – С. 95-96.

10. Селиванов Е.А., Софронов Г.А., Ханевич М.Д. и др. Эффективность применения перфторана в хирургической практике // Трансфузиология. – 2008. – № 2. – С. 78-88.

11. Селиванов Е.А., Софронов Г.А., Ханевич М.Д., Скрябин О.Н. Возможности применения модифицированного гемоглобина в хирургии // Трансфузиология. – 2008. – Т.9. – № 2. – С. 68-77.

12. Склифас А.Н., Шехтман Д.Г., Образцов В.В. и др. Механизмы распределения и выведения перфторуглеродов при многократных введениях // Биофизика. – 1998. – Т.43. – №1. – С. 171-176.

13. Софронов Г.А., Селиванов Е.А., Ханевич М.Д. Переносчики кислорода: состояние проблемы и перспективы развития // Применение инфузионных антигипоксантов и искусственных переносчиков кислорода в хирургии: Сб. науч. тр. / СПб. 1999. – С. 75-85.

14. Сухоруков В.П., Рагимов А.А., Пушкин С.Ю. и др. Перфторан – перфторуглеродный кровезаменитель с газотранспортной функцией // Пособие для врачей. – 2-е изд., перераб. и доп. / Москва.: Б.и., 2008.

15. Филатов Ф.П. Вирусная безопасность переливания крови // Природа. 2005. № 3. URL: http://vivovoco.rsl.ru/VV/JOURNAL/NATURE/03_05/VIRUS.HTM

16. Ханевич М.Д., Софронов Г.А., Селиванов Е.А., Корик В.Е. Применение искусственного переносчика кислорода на основе модифицированного гемоглобина у больных с гастродуоденальными кровотечениями // Вестн. хирургии им. И.И. Грекова. 2000. – Т. 159. – № 6. – С. 51-54.

17. Шевченко Ю.Л., Шабалин В.Н., Заривчацкий М.Ф., Селиванов Е.А. Руководство по общей и клинической трансфузиологии // СПб.: «Фолиант», 2003.

18. Ярочкин В.С., Кочемасов В.В. Гемодилюция. Настоящее и будущее // М.: Б.и., 1997.

19. Alayash A.I. Redox and Radical Reactions of Hemoglobin Solutions: Toxicities and Protective Strategies // In: Blood Substitutes. Ed. by R. Winslow / San Diego: Academic Press, 2006. – P. 197-205.

20. Amberson W.R. Blood substitutes // Biol. Rev. 1937. Vol. 12. P. 48-85.

21. Benesch R.E., Benesch R., Renthal R.D., Maeda N. Affinity labeling of the polyphosphate binding site of hemoglobin // Biochemistry. – 1972. – Vol. 11. – № 19. – Р. 3576- 3582.

22. Björkholm M., Fagrell B., Przybelski R. et al. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human Hb modified with maleimide-activated polyethylene glycol // Haematologica. – 2005. – Vol. 90. – № 4. – P. 505-515.

23. Blood substitutes. Ed. by R. Winslow / San Diego: Academic Press. – 2006.

24. Carmichael F.J., Ali A.C., Campbell J.A. et al. A phase I study of oxidized raffinose cross-linked human hemoglobin // Crit. Care Med. – 2000. – Vol. 28. – № 7. – P. 2283- 2292.

25. Carson J.L., Noveck H., Berlin J.A., Gould S.A. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion // Transfusion. – 2002. – Vol. 42. – № 7. – Р. 812-818.

26. Chang T.M. A nanobiotechnologic therapeutic that transport oxygen and remove oxygen radicals: for stroke, hemorrhagic shock and related conditions // In: Artificial cells: biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation and cell/stem cell therapy. Ed. by T.M. Chang / Singapore: World Science Publisher, 2007. P. 62-92.

27. Chang T.M. Nanobiotechnology for Hemoglobin-based blood substitutes // Crit. Care Clin. – 2009. – Vol. 25. – № 2. – P. 373-382.

28. Cheng D.C. Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolink) in cardiac surgery // Can. J. Anaesth. – 2001. – Vol. 48. – № 4 (Suppl.) – S. 41-48.

29. Cohn C.S., Cushing M.M. Oxygen therapeutics: perfluorocarbons and blood substitute safety // Crit. Care Clin. – 2009. – Vol. 25. – № 2. – P. 399-414.

30. D’Agnillo F., Chang T.M. Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties // Nat. Biotechnol. – 1998. – Vol.16. – № 7. – Р. 667-671.

31. Drobin D., Kjellstrom B.T., Malm E. et al. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4) // J. Appl. Physiol. – 2004. – Vol. 96. – № 5. – P. 1843-1853.

32. Epstein J.S., Holmberg J.A. Progress in monitoring blood safety // Transfusion. – 2010. – Vol. 50. – № 7. – P. 1408-1412.

33. Gould S.A., Moore E.E., Hoyt D.B. et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery // J. Am. Coll. Surg. – 1998. – Vol. 187. – № 2. – Р. 113-120.

34. Gould S.A., Moore E.E., Hoyt D.B. et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable // J. Am. Coll. Surg. – 2002. – Vol. 195. – № 4. – Р. 445-452.

35. Gould S.A., Moore E.E., Moore F.A. et al. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery // J. Trauma. – 1997. – Vol. 43. – № 2. – Р. 325-331.

36. Greenburg A.G., Kim H.W. Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery // J. Am. Coll. Surg. – 2004. – Vol. 198. – № 3. – Р. 373- 385.

37. Henkel-Honke T., Oleck M. Artificial oxygen carriers: a current review // AANA J. – 2007. – Vol. 75. – № 3. – P. 205-211.

38. Hill S.E., Gottschalk L.I., Grichnik K. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery // J. Cardiothorac. Vasc. Anesth. – 2002. – Vol. 16. – № 6. – Р. 695-702.

39. Hoffman S.J., Looker D.L., Roehrich J.M. et al. Expression of fully functional tetrameric human hemoglobin in Escherichia coli // Proc. Natl. Acad. Sci. USA. – 1990. – Vol. 87. – № 21. – Р. 8521-8525.

40. Izumi Y., Sakai H., Kose T. et al. Evaluation of the capabilities of a hemoglobin vesicle as an artificial oxygen carrier in a rat exchange transfusion model // ASAIO J. – 1997. – Vol. 43. – № 4. – Р. 289-297.

41. Jahr J.S., Varma N. PolyHeme. Northfield Laboratories // IDrugs. – 2004. – Vol. 7. – № 5. – Р. 478-482.

42. Jahr J.S., Weeks, D.L., Desai, P. et al. Does OxyVita, a new-generation hemoglobin based oxygen carrier, or Oxyglobin acutely interfere with coagulation compared with normal saline or 6% hetastarch? // J. Cardiothorac. Vas. Anesth. – 2008. – Vol. 22. – № 1. – Р. 34-38.

43. Jia Y., Alayash A.I. Effects of cross-linking and zero-link polymerization on oxygen transport and redox chemistry of bovine hemoglobin // Biochim. Biophys. Acta. – 2009. – Vol. 1794. – № 8. – P. 1234-1242.

44. Kasper S.M., Walter M., Grüne F. et al. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery // Anesth. Analg. – 1996. – Vol. 83. – № 5. – Р. 921-927.

45. Kerger H., Tsai A.G., Saltzman D.J. et al. Fluid resuscitation with O2 vs. non-O2 carriers after 2 h of hemorrhagic shock in conscious hamsters // Am. J. Physiol. – 1997. – Vol. 272. – № 1 (Pt. 2) – H525-537.

46. Kerner T., Ahlers O., Veit S. et al. DCL-Hb for trauma patients with severe hemorrhagic shock: the European "On-Scene" multicenter study // Intensive Care Med. – 2003. – Vol. 29. – № 3. – Р. 378-385.

47. Kim H.W., Greenburg A.G. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status // Artif. Organs. – 2004. – Vol. 28. – № 9. – P. 813-828.

48. Kim H.W ., Greenburg A.G. Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others // Artif. Cells Blood Substit. Immobil. Biotechnol. – 2006. – Vol. 34. – № 6. – Р. 537-550.

49. LaMuraglia G.M., O'Hara P.J., Baker W.H. et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution // J. Vasc. Surg. – 2000. – Vol. 31. – № 2. – Р. 299-308.

50. Lamy M.L., Daily E.K., Brichant J.F. et al. Randomized trial of diaspirin crosslinked hemoglobin solution as an alternative to blood transfusion after cardiac surgery // Anesthesiology. – 2000. – Vol. 92. – № 3. – Р. 646-656.

51. Levy J.H., Goodnough L.T., Greilich P.E. et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial // J. Thorac. Cardiovasc. Surg. – 2002. – Vol. 124. – № 1. – Р. 35-42.

52. Loeb A.L., McIntosh L.J., Raj N.R., Longnecker D.E. Resuscitation after hemorrhage using recombinant human hemoglobin (rHb1.1) in rats: effects on nitric oxide and prostanoid systems // Crit. Care Med. – 1998. – Vol. 26. – № 6. – Р. 1071-1080.

53. Looker D., Abbott-Brown D., Cozart P. et al. A human recombinant haemoglobin designed for use as a blood substitute // Nature. – 1992. – Vol. 356. – № 6366. – Р. 258-260.

54. Lowe K.C. Genomics and blood substitutes for 21st century Europe ("EuroBloodSubstitutes") // Artif. Cells Blood Substit. Immobil. Biotechnol. – 2006. – Vol. 34. – № 6. – P. 589-599.

55. Lowenstein C.J., Dinerman J.L., Snyder S.H. Nitric oxide: a physiologic messenger // Ann. Intern. Med. – 1994. – Vol. 120. – № 3. – Р. 227-237.

56. Malhotra A.K., Kelly M.E., Miller P.R. et al. Resuscitation with a novel hemoglobin-based oxygen carrier in a Swine model of uncontrolled perioperative hemorrhage // J. Trauma. – 2003. – Vol. 54. – № 5. – Р. 915-924.

57. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology // Pharmacol. Rev. – 1991. – Vol.43. – № 2. – Р. 109-142.

58. Moore E.E., Moore F.A., Fabian T.C. et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial // J. Am. Coll. Surg. – 2009. – Vol. 208. – № 1. – P. 1-13.

59. Moskowitz D.M ., McCullough J.N., Shander A. et al. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective? // Ann. Thorac. Surg. – 2010. – Vol. 90. – № 2. – Р. 451-458.

60. Murphy G.J., Reeves B.C., Rogers C.A. et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery // Circulation. – 2007. – Vol. 116. – № 22. – P. 2544–2552.

61. Nakaki T. Physiological and clinical significance of nitric oxide // Keio J. Med. – 1994. – Vol. 43. – № 1. – Р. 15-26.

62. Natanson C., Kern S.J., Lurie P. et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis // JAMA. – 2008. – Vol. 299. – № 19. – P. 2304-2312.

63. Ness P.M., Cushing M.M. Oxygen therapeutics. Pursuit of an alternative to the donor red blood cell // Arch. Pathol. Lab. Med. – 2007. – Vol. 131. – № 5. – P. 734-741.

64. Ning J., Wong L.T., Christoff B. et al. Haemodynamic response following a 10% topload infusion of HemolinkTM in conscious, anaesthetized and treated spontaneously hypertensive rats // Transfus. Med. – 2000. – Vol. 10. – № 1. – Р. 13-22.

65. Olofsson C., Ahl T., Johansson T. et al. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery // Anesthesiology. – 2006. – Vol. 105. – № 6. – P. 1153-1163.

66. Pearce L.B., Gawryl M.S., Rentko V.T. et al. HBOC-201 (Hemoglobin Glutamer- 250 (Bovine), Hemopure®): Clinical studies // In: Blood substitutes. Ed. by R. Winslow / San Diego: Academic press, 2006. – P. 437-450.

67. Pirie E., Green J. A framework to support safe blood transfusion practice // Nurs. Stand. – 2010. – Vol. 24. – № 48. – P. 35-40.

68. Powanda D.D., Chang T.M. Cross-linked polyhemoglobin-superdioxide dismutase-catalase supplies oxygen without causing blood-brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion // Art. Cells Blood Subsstit. Immobil. Biotechnol. – 2002. – Vol. 30. – № 1. – P. 25-42.

69. Riess J.G. Oxygen carriers (“blood substitutes”) - raison d’etre, chemistry and some physiology // Chem. Rev. – 2001. – Vol.101. – № 9. – P. 2797-2920.

70. Saezler R.K., Arfors K.E., Tuma R.F. et al. Polynitroxylated hemoglobin-based oxygen carrier: inhibition of free radical induced microcirculatory dysfunction // Free Radic. Biol. Med. – 1999. – Vol. 27. – № 1-2. – P. 1-6.

71. Sakai H., Horinouchi H., Yamamoto M. et al. Acute 40 percent exchangetransfusion with hemoglobin-vesicles (HbV) suspended in recombinant human serum albumin solution: Degradation of HbV and erythropoiesis in a rat spleen for 2 weeks // Transfusion. – 2006. – Vol. 46. – № 3. – Р. 339-347.

72. Sakai H., Masada Y., Horinouchi H. et al. Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats // Crit. Care Med. – 2004. – Vol. 32. – № 2. – Р. 539-545.

73. Sakai H., Sou K., Horinouchi H. et al. Hemoglobin-vesicles as artificial oxygen carriers: present situation and future visions // J. Intern. Med. – 2008. – Vol. 263. – № 1. – P. 4- 15.

74. Sakai H., Sou K., Horinouchi H. et al. Review of hemoglobin-vesicles as artificial oxygen carriers // Artif. Organs. – 2009. – Vol. 33. – № 2. – Р. 139-145.

75. Sakai H., Sou K., Tsuchida E. Hemoglobin-vesicles as an artificial oxygen carrier // Methods Enzymol. – 2009. – Vol. 465. – P. 363-384.

76. Sakai H., Takeoka S., Park S.I. et al. Surface modification of hemoglobin vesicles with poly(ethylene glycol) and effects on aggregation, viscosity, and blood flow during 90% exchange transfusion in anesthetized rats // Bioconjug. Chem. – 1997. – Vol.8. – №1. – Р. 23-30.

77. Sakai H., Tomiyama K., Sou K. et al. Poly(ethylene glycol)-conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state// Bioconjug. Chem. – 2000. – Vol. 11. – № 3. – Р. 425-432.

78. Savitsky J.P., Doczi J., Black J., Arnold J.D. Clinical safety trial of stroma-free hemoglobin // Clin. Pharmacol. Ther. – 1978. – Vol. 23. – № 1. – Р. 73-80.

79. Schubert A., Przybelski R.J., Eidt J.F. et al. Diaspirin-crosslinked hemoglobin reduces blood transfusion in noncardiac surgery: a multicenter, randomized, controlled, doubleblinded trial // Anesth. Analg. – 2003. – Vol. 97. – № 2. – Р. 323-332.

80. Selivanov E.A., Kochetygov N.L., Bistrova I.M. et al. Study of polymerized hemoglobin in experiment // Artif. Cells Blood Substit. Immobil. Biotechnol. – 1994. – Vol. 22. – № 5. – P. 156.

81. Siegel J.H., Fabian M., Smith J.A., Costantino D. Use of recombinant hemoglobin solution in reversing lethal hemorrhagic hypovolemic oxygen debt shock // J. Trauma. – 1997. – Vol. 42. – № 2. – Р. 199-212.

82. Simoni J. Artificial oxygen carriers: scientific and biotechnological points of view // Artif. Organs. – 2009. – Vol. 33. – № 2. – P. 92-96.

83. Simoni J. Endothelial cell response to hemoglobin based oxygen carriers. Is the attenuation of pathological reactions possible? // In: Artificial Oxygen Carrier. Its Front Line. Kobayashi K, Tsuchida E, Horinouchi H, eds. / Tokyo: Springer-Verlag, 2005. – Р. 25-75.

84. Simoni J., Simoni G., Moeller J.F. Intrinsic toxicity of hemoglobin: how to counteract it // Artif. Organs. – 2009. – Vol. 33. – № 2. – P. 100-109.

85. Simoni J., Villanueva-Meyer J., Simoni G. et al. Control of oxidative reactions of hemoglobin in the design of blood substitutes: role of the ascorbate-glutathione antioxidant system // Artif. Organs. – 2009. – Vol. 33. – № 2. – P. 115-126.

86. Sloan E.P., Koenigsberg M., Gens D. et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial // JAMA. – 1999. – Vol. 282. – № 19. – Р. 1857-1864.

87. Sou K., Klipper R., Goins B., et al. Circulation kinetics and organ distribution of Hb vesicles developed as a red blood cell substitute // J. Pharmacol. Exp. Ther. - 2005. - Vol. 312. - Р.702-709.

88. Spahn D.R., Kocian R. Artificial O2 carriers: status in 2005 // Curr. Pharm. Des. – 2005. – Vol.11. – № 31. – P. 4099-4114.

89. Sprung J., Kindscher J.D., Wahr J.A. et al. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: Results of a multicenter, randomized single-blind study // Anesth. Analg. – 2002. – Vol. 94. – № 4. – Р. 799-808.

90. Stowell C.P., Levin J., Spiess B.D., Winslow R.M. Progress in the development of RBC substitutes // Transfusion. – 2001. – Vol. 41. – № 2 – Р. 287-299.

91. Strauss R.G. Blood banking issues pertaining to neonatal red blood cell transfusions // Transfus. Sci. – 1999. – Vol.21. – № 1. – P. 7-19.

92. Tsai A.G., Vandegriff K.D., Intaglietta M., Winslow R.M. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics // Am. J. Physiol. – 2003. – Vol. 285. – № 4. – P. 1411-1419.

93. Vamvakas E.C., Taswell H.F. Epidemiology of blood transfusion // Transfusion. – 1994. – Vol.34. – № 6. – P. 464-470.

94. Vandegriff K., Winslow R.M. Hemospan: design principles for a new class of oxygen therapeutic // Artif. Organs. – 2009. – Vol. 33. – № 2. – P. 133-138.

95. Vandegriff K.D., Malavalli A., Wooldridge J. et al. MP4, a new nonvasoactive PEG-Hb conjugate // Transfusion. – 2003. – Vol. 43. – №4. – Р. 509-516.

96. von Dobschuetz E., Hutter J., Hoffmann T., Messmer K. Recombinant human hemoglobin with reduced nitric oxide-scavenging capacity restores effectively pancreatic microcirculatory disorders in hemorrhagic shock // Anesthesiology. – 2004. – Vol. 100. – № 6. – Р. 1484-1490.

97. Winslow R. Current status of blood substitute research: towards a new paradigm // J. Intern. Med. – 2003. – Vol. 253. – №5. – P. 508–517.

98. Winslow R.M., Chapman K.W., Vandegriff K.D., Young M. Hemospan® (MP4), A human hemoglobin modified with maleimide-polyethylene glycol // In: Blood Substitutes. Ed. by R. Winslow / San Diego: Academic Press, 2006. – P. 470-482.

99. Winslow R.M., Lohman J., Malavalli A., Vandegriff K.D. Comparison of PEGmodified albumin and hemoglobin in extreme hemodilution in the rat // J. Appl. Physiol. – 2004. – Vol. 97. – № 4. – P. 1527–1534.

100. Wong N., Chang T.M. Polyhemoglobin-fibrinogen: a novel oxygen carrier with platelet-like properties in a hemodiluted setting// Art. Cells Blood Substit. Immobil. Biotechnol. – 2007. – Vol. 35. – № 5. – P. 481-489.

101. Yazer M.H., Triulzi D.J. Receipt of older RBCs does not predispose D-negative recipients to anti-D alloimmunization // Am. J. Clin. Pathol. – 2010. – Vol. 134. – № 3. – Р. 443- 447.

102. Young M.A., Lohman J., Malavalli A. et al. Hemospan improves outcome in a model of peri-operative hemodilution and blood loss in the rat: comparison with hydroxyethyl starch // J. Cardiothorac. Vasc. Anesth. – 2009. – Vol. 23. – № 3. – Р. 339-347.

103. Young M.A., Riddez L., Kjellström B.T. et al. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine // Crit. Care Med. – 2005. – Vol. 33. – № 8. – P. 1794-1804.

104. Zhu X., Chu W., Wang F. et al. Variations in dominant antigen determinants of glutaraldehyde polymerized human, bovine and porcine hemoglobin // Art. Cells Blood Substit. Immobil. Biotechnol. – 2007. – Vol. 35. – № 5. – P. 518-532.